Influencing Physician Prescribing: Does Clinical Data Work?
At the 2002 American Heart Association meeting last November, many cardiologists could be heard expressing frustration over how to interpret and apply clinical data in their day-to-day practices. At the same time, thought leaders involved in generating the periodic guideline recommendations designed to interpret such data could be heard complaining about the low rate of compliance with guidelines. Both are addressing the same core issue: How does data change practice patterns for the better, and how can that change be made rapidly and effectively given the time it takes to complete and analyze a data set on potential outcomes?
You may also be interested in...
The history of the IIb/IIIa inhibitor Integrilin touches on many of the challenges of cardiology marketing, including how to move a member of a new class of drugs into a complex, rapidly evolving treatment pattern. Having established Integrilin as the most-used drug in its class, its marketer must now deal with the impact on IIb/IIIa use of Angiomax, a potential replacement for heparin. Imagine the scene five years from now: A combination of Angiomax and low-molecular-weight heparin has replaced unfractionated heparin, and the addition of statins and possibly vascular protectants has turned the current triple therapy regimens of anti-coagulants, anti-thrombins, and anti-platelet drugs into a quartet. Physicians attending scientific meetings may well still be puzzling over the proper role of IIb/IIIa inhibitors, and asking themselves the extent to which long-term results from trials initiated early in the 21st century have meaning.